Cellectis S.A. (EPA:ALCLS)
3.105
+0.095 (3.16%)
Apr 2, 2026, 5:35 PM CET
Cellectis Revenue
In the year 2025, Cellectis had annual revenue of $79.59M USD with 61.72% growth. Cellectis had revenue of $12.21M in the quarter ending December 31, 2025, a decrease of -19.51%.
Revenue
$79.59M
Revenue Growth
+61.72%
P/S Ratio
3.32
Revenue / Employee
$347.57K
Employees
229
Market Cap
225.40M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Adocia | 12.88M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| ABIONYX Pharma | 4.10M |
Cellectis News
- 15 days ago - Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 22 days ago - Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - GlobeNewsWire
- 4 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 3 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 3 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 3 months ago - Cellectis Announces Arbitral Decision in Dispute with Servier - GlobeNewsWire
- 4 months ago - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL - GlobeNewsWire
- 4 months ago - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells - GlobeNewsWire